Company Name
Alicorn Pharmaceutical Co., Ltd
Year of Establishment
2021
Annual Turnover(USD)
500,000 to 99,999,999
Company Introduction
Brief Introduction
Alicorn pharmaceutical Co.,Ltd is a national high-tech enterprise engaged in the R&D and manufacturing of innovative drugs、modified new drugs、generic drugs and pharmaceutical intermediates.It has been been equipped with two R&D centers respectively in Nanjing Jiangsu province and Jiaxing Zhejiang province of China.Our own wholly owned manufacturing site is located in Anqing high-tech industry zone of Anhui province,the manufacturing site is used to produce the APIs and final drugs covering an area of 72mu.
Our business scope
R&D and registration
Research and development of generic drugs
Research and development of innovative drugs
Conformance evaluation of generic drugs
Process optimization and changes of APIs and final drugs
Patent strategic consulting
Application and registration consulting
Technical service and consulting
Customization and production
New molecular compound customized synthesis
Pharmaceutical intermediates customized manufacturing
APIs customized manufacturing
APIs and final drugs joint development
APIs contract manufacturing
Final drugs contract manufacturing
Nanjing R&D center
It covers an area of 1800 square meters,mainly dedicated in the process research and optimization of APIs 、pharmaceutical intermediates、solid & liquid drugs and quality & stability research.
Jiaxing R&D center
It covers an area of over 3500 square meters,mainly participated in the customization and synthesis of new molecular compound.
Anqing Technical center ( under construction)
The lab has an area of 1200 square meters,mainly used for the process optimization、finalize、scale-up and costing control of APIs and pharmaceutical intermediates.
Anqing manufacturing base
Land area: 48000 square meters
Gross floor area: 40000 square meters
The APIs & intermediates manufacturing site covers an area of 15000 square meters, the 500-5000L reactors can be available for specific reactions including high temperature、high pressure、cryogenic and hydrogenation reactions.
The final drugs manufacturing site has an area of 11000 square meters for the production of oral solid drugs and external drugs.
Main Competitive Advantages
International Approvals/Standards,Experienced R&D Staff,Contract Manufacturing (CRO,CMO),Reputation,Quality Service,
Other Competitive Advantages
Three R&D centers and one manufacturing base.
Nanjing R&D center
It covers an area of 1800 square meters,mainly dedicated in the process research and optimization of APIs 、pharmaceutical intermediates、solid & liquid drugs and quality & stability research.
Jiaxing R&D center
It covers an area of over 3500 square meters,mainly participated in the customization and synthesis of new molecular compound.
Anqing Technical center ( under construction)
The lab has an area of 1200 square meters,mainly used for the process optimization、finalize、scale-up and costing control of APIs and pharmaceutical intermediates.
Anqing manufacturing site.
The APIs & intermediates manufacturing site covers an area of 15000 square meters, the 500-5000L reactors can be available for specific reactions including high temperature、high pressure、cryogenic and hydrogenation reactions
The final drugs manufacturing site has an area of 11000 square meters for the production of oral solid drugs and external drugs.
Patents and Copyright
We have applied several patents for the R&D of APIs and drugs
Milestone
2015.05 : Jiangsu Alicorn medical & technology Co.Ltd establish
2015.07: Nanjing R&D center put into operation
2018.12: Rewarded as National High-tech enterprises.
2019.10: Anhui Alide pharmaceutical Co.,Ltd established
2021.01: Alicorn Pharmaceutical Co.,Ltd established
2021.03: Anhui Alide pharmaceutical Co.,Ltd construction started
2021.07: Zhejiang R&D center put into operation.